Callan Capital’s Halozyme HALO Stock Holding History

Callan Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$397K	Buy	6,222 +35	+0.6%	+$2.03K	0.03%	236
2024 Q4	$296K	Sell	6,187 -69	-1%	-$3.54K	0.02%	256
2024 Q3	$358K	Buy	6,256 +1,049	+20%	+$60.1K	0.03%	236
2024 Q2	$273K	Buy	5,207 +79	+2%	+$3.46K	0.02%	250
2024 Q1	$209K	Buy	+5,128	New	+$192K	0.02%	271
2023 Q1	–	Sell	-4,770	Closed	-$271K	–	189
2022 Q4	$271K	Buy	+4,770	New	+$244K	0.03%	152
2015 Q4	–	Sell	-12,230	Closed	-$164K	–	66
2015 Q3	$164K	Buy	+12,230	New	+$246K	0.09%	60
2015 Q2	–	Sell	-64,431	Closed	-$920K	–	72
2015 Q1	$920K	Sell	64,431 -134,799	-68%	-$1.94M	0.2%	43
2014 Q4	$1.92M	Hold	199,230	–	–	0.44%	32
2014 Q3	$1.81M	Hold	199,230	–	–	0.5%	26
2014 Q2	$1.97M	Buy	199,230 +34,230	+21%	+$290K	0.53%	27
2014 Q1	$2.1M	Hold	165,000	–	–	0.7%	23
2013 Q4	$2.47M	Hold	165,000	–	–	0.95%	23
2013 Q3	$1.82M	Buy	165,000 +20,000	+14%	+$167K	0.87%	23
2013 Q2	$1.15M	Buy	+145,000	New	+$923K	0.66%	25

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Callan Capital's HALO Position: Q1 2025 in Review

Callan Capital increased its Halozyme (HALO) stake by 0.57% in Q1 2025, buying an estimated $2.03K and bringing the position to 6,222 shares worth $397K. The position accounts for 0.03% of the portfolio, ranked #236.

Callan Capital first reported a position in HALO in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.47M in Q4 2013. 550 funds tracked by Wall St. Rank hold HALO as of Q1 2025.

Callan Capital held 6,222 shares of Halozyme worth $397K as of Q1 2025.
Callan Capital bought 35 Halozyme shares in Q1 2025, an estimated $2.03K.
Halozyme made up 0.03% of Callan Capital's portfolio in Q1 2025, its #236 holding.
Callan Capital first reported a position in Halozyme in Q2 2013 and has held it in 15 quarters since.
Callan Capital's Halozyme position peaked at $2.47M in Q4 2013.
550 funds tracked by Wall St. Rank held Halozyme as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.